Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 41739590 | 2026 | Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer. Cancer immunology research Likely relevant The study experimentally tests anti-PD-1 therapy in animal models and reports its effect on CD8+ T-cell infiltration, Ly6C+ monocytes, and proinflammatory macrophages. | anti-PD-1 | Animal | lung cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 41766908 | 2026 | Association between peripheral IFN-γ+ cytotoxic lymphocytes and response to PD-1/PD-L1-based therapy in hepatocellular carcinoma. Frontiers in immunology Likely relevant The study evaluates cancer patients treated with PD-1 inhibitors alone or in combination with TKIs or bevacizumab and measures peripheral immune cell proportions and IFN-g production. | PD-1/PD-L1-based therapies; tyrosine kinase inhibitors; bevacizumab | Patient | hepatocellular carcinoma | PD-1/PD-L1-based therapies 0/0/0; tyrosine kinase inhibitors 0/0/0; bevacizumab 0/0/7 | Awaiting curator check |
| 41791704 | 2026 | Targeting the Golgi apparatus enhances PD-L1 blockade and synergizes with oxaliplatin to improve immunotherapy efficacy. The Journal of biological chemistry Likely relevant The study tests oxaliplatin and PD-L1 targeted liposomal formulations in mouse tumor models, assessing immunogenic cell death and sustained antitumor immunity. | oxaliplatin; PD-L1 blockade; chondroitin sulfate-modified liposomal formulation | Animal | breast cancer, melanoma, lung cancer | oxaliplatin 12/5/2; PD-L1 blockade 0/4/0; chondroitin sulfate-modified liposomal formulation 0/0/0 | Awaiting curator check |
| 41792510 | 2026 | Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells. British journal of cancer Likely relevant The study tests PAK inhibitors and PD-1 blockade in cell line co-cultures and measures CD8+ T cell-mediated killing and PD-L1 expression. | PAK inhibitors; PD-1 checkpoint blockade | Cell line | ovarian cancer | PAK inhibitors 0/0/0; PD-1 checkpoint blockade 0/0/0 | Awaiting curator check |
| 41851187 | 2026 | Tumor-suppressing multi-enterobacteria enhance the anti-PD-1/PD-L1 efficacy in microsatellite stable colorectal cancer. Scientific reports Likely relevant The study experimentally tests probiotic consortia combined with anti-PD-1/anti-PD-L1 in tumor-bearing mice and reports effects on CD8+ T cell infiltration and cytokine profiles. | anti-PD-1; anti-PD-L1; Tumor-Suppressing Multi-Enterobacteria | Animal | colorectal cancer | anti-PD-1 14/36/0; anti-PD-L1 0/15/0; Tumor-Suppressing Multi-Enterobacteria 0/0/0 | Awaiting curator check |
| 41901681 | 2026 | Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. Medicina (Kaunas, Lithuania) Likely relevant The study tests the combination of paclitaxel and atezolizumab in an experimental TNBC model and measures PD-L1 expression in myeloid cells and immune infiltration. | paclitaxel; atezolizumab | Animal | triple-negative breast cancer (TNBC) | paclitaxel 21/5/8; atezolizumab 0/0/4 | Awaiting curator check |
| 41916996 | 2026 | PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma. Nature communications Likely relevant The study tests TKIs and immune checkpoint inhibitors in patients and in vivo mouse models, reporting effects on neutrophil infiltration and tumor microenvironment remodeling. | tyrosine kinase inhibitors; immune checkpoint inhibitors; anti-PD-1 | Mixed | advanced renal cell carcinoma | tyrosine kinase inhibitors 0/0/0; immune checkpoint inhibitors 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 41932527 | 2026 | H3K27ac-induced IFITM3 promotes progression of TNBC and resistance to anti-PD-1/PD-L1 therapy via the TNF-α/NF-κB/PD-L1 axis. Biochimica et biophysica acta. Molecular basis of disease Likely relevant The study investigates the role of IFITM3 and evaluates the effects of anti-PD-1 therapy in vitro and in vivo (tumor xenografts) measuring CD8+ T-cell infiltration. | anti-PD-1/PD-L1 therapy | Mixed | triple-negative breast cancer | anti-PD-1/PD-L1 therapy 0/0/0 | Awaiting curator check |
| 41935049 | 2026 | Inhibition of circulating glycocholic acid-regulated signaling potentiates immune checkpoint therapy in colorectal cancer. Nature communications Likely relevant The study evaluates anti-PD-1 therapy in a mouse colorectal cancer model and measures CD8+ T cell-mediated immunity. | anti-PD-1 | Animal | Colorectal cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 41956544 | 2026 | Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets. Journal for immunotherapy of cancer Likely relevant The study tests checkpoint therapies and a novel anti-KLRG1 monoclonal antibody in mouse models and human T cells, assessing lymphocyte activation and tumor infiltration. | anti-programmed death-1 (PD-1); anti-human KLRG1 monoclonal antibody | Mixed | melanoma | anti-programmed death-1 (PD-1) 0/0/0; anti-human KLRG1 monoclonal antibody 0/0/0 | Awaiting curator check |
| 41988184 | 2026 | Iodine-125 brachytherapy triggers immunogenic cell death and potentiates anti-PD-L1 immunotherapy in bone metastatic triple-negative breast cancer. Frontiers in immunology Likely relevant The study experimentally tests iodine-125 brachytherapy alone or with anti-PD-L1 and Abraxane in a mouse breast cancer model, measuring ICD biomarkers, CD8+ T cell infiltration, and systemic antitumor immunity. | iodine-125; anti-PD-L1 antibody; Abraxane | Animal | triple-negative breast cancer | iodine-125 0/0/0; anti-PD-L1 antibody 0/1/0; Abraxane 0/0/0 | Awaiting curator check |
| 41991507 | 2026 | Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance. Signal transduction and targeted therapy Likely relevant The study experimentally tests an anti-AXL monoclonal antibody alone and in combination with immune checkpoint blockade in vivo, measuring macrophage uptake, interferon production, dendritic cell activation, and T-cell infiltration. | monoclonal antibody (6C5); anti-PD-1; anti-CTLA-4; PD-1-targeted IL-2 fusion protein | Mixed | unspecified | monoclonal antibody (6C5) 0/0/0; anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; PD-1-targeted IL-2 fusion protein 0/0/0 | Awaiting curator check |
| 42002768 | 2026 | Biomimetic nanodecoys remodel the mechano-immune microenvironment to potentiate checkpoint blockade in colorectal cancer. Journal of nanobiotechnology Likely relevant Tests a biomimetic nanoplatform delivering Defactinib and PD-L1 antibodies in mouse models and measures cytotoxic T cell infiltration. | Defactinib; PD-L1 antibody | Animal | colorectal cancer | Defactinib 0/0/0; PD-L1 antibody 0/1/0 | Awaiting curator check |
| 42168481 | 2026 | Trifluridine/tipiracil enhances radiation-induced abscopal effects and augments PD-1 blockade in gastric cancer. Scientific reports Likely relevant Tests trifluridine/tipiracil, radiation therapy, and anti-PD-1 in mouse cancer cells and subcutaneous tumor models, measuring immunogenic cell death and immune cell infiltration. | trifluridine/tipiracil; anti-PD-1 | Mixed | gastric cancer | trifluridine/tipiracil 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 42208981 | 2026 | CLEC2B-KLRB1 axis acts as an immune checkpoint, governing the exhaustion of CD8+ T cells and their resistance to immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant The study tests blocking antibodies against the CLEC2B-KLRB1 axis in cellular experiments and mouse models, measuring changes in CD8+ T-cell exhaustion and antitumor function. | KLRB1 blocking antibodies | Mixed | colorectal cancer | KLRB1 blocking antibodies 0/0/0 | Awaiting curator check |
| 42238595 | 2026 | Huayu Wan enhances immune checkpoint inhibitor efficacy in triple-negative breast cancer by normalizing tumor vasculature and remodeling the tumor immune microenvironment. Frontiers in immunology Likely relevant The study experimentally tests Huayu Wan combined with immune checkpoint inhibitors in a TNBC animal model and cell assays, measuring CD8+ T cell infiltration, effector cytokines, and exhaustion markers. | Huayu Wan; immune checkpoint inhibitors | Mixed | triple-negative breast cancer | Huayu Wan 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 42243329 | 2026 | Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. Oncogene Likely relevant The study experimentally tests intratumoral sodium bicarbonate combined with Tislelizumab in murine models and patients, measuring immune cell recruitment, activation, and T-cell infiltration. | Tislelizumab; sodium bicarbonate | Mixed | hepatocellular carcinoma | Tislelizumab 0/0/0; sodium bicarbonate 0/0/0 | Awaiting curator check |
| 42270598 | 2026 | CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma. Cell death & disease Likely relevant The study investigates CFTR activation combined with PD-L1 antibodies using human/murine HCC cell lines, mouse models, and organoids, measuring cytokine levels, macrophage polarization, and T cell infiltration. | PD-L1 antibody; PD-1/PD-L1 monoclonal antibodies | Mixed | Hepatocellular carcinoma | PD-L1 antibody 0/1/0; PD-1/PD-L1 monoclonal antibodies 0/0/0 | Awaiting curator check |
| 42308603 | 2026 | Legumain-activated radio-immunological synergist potentiates the abscopal effect via dual CD47/PD-L1 blockade and macrophage repolarization. Biomaterials Likely relevant The study tests a legumain-activated radio-immunological synergist in vitro and in vivo, assessing macrophage repolarization, checkpoint expression, and systemic antitumor immunity. | LARIS (bispecific immune checkpoint blockade chimeric peptide + R848) | Mixed | breast cancer | LARIS (bispecific immune checkpoint blockade chimeric peptide + R848) 0/0/0 | Awaiting curator check |
| 42314991 | 2026 | Reversing immunotherapy resistance in cold tumors by weaponizing pyroptosis with a dual-payload nanotuner. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The article experimentally tests a dual-payload nanoparticle (GSDME mRNA and 1541B) combined with anti-PD-1 in tumor-bearing mice and measures pro-inflammatory cytokines and tumor immune microenvironment remodeling. | anti-PD-1; GSDME mRNA; 1541B | Animal | tumor | anti-PD-1 14/36/0; GSDME mRNA 0/0/0; 1541B 0/0/0 | Awaiting curator check |
| 42322856 | 2026 | Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology Likely relevant The study tests gemcitabine and anti-PD-L1 in human and mouse colorectal cancer cell lines and mouse models, measuring T cell infiltration, cytokines, and PD-L1 expression. | gemcitabine; anti-PD-L1 | Mixed | colorectal cancer | gemcitabine 30/23/10; anti-PD-L1 0/15/0 | Awaiting curator check |
| 42330494 | 2026 | Cancer-Intrinsic Protein Neddylation Modulates the Intratumoral Immune Landscape to Constrain Immune Checkpoint Blockade Therapy. Cancer immunology research Likely relevant Tests lipid inhibitors, ferroptosis inducers, and PD-1/PD-L1 blockade in combination with genetic or pharmacological targeting and measures effects on T-cell expansion and antitumor immunity. | pembrolizumab; lipid inhibitors; ferroptosis inducers; PD-1 or PD-L1 blockade | Mixed | breast cancer | pembrolizumab 0/0/16; lipid inhibitors 0/0/0; ferroptosis inducers 0/0/0; PD-1 or PD-L1 blockade 0/0/0 | Awaiting curator check |
| 42358824 | 2026 | Germinal Center-Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer. Oncology research Likely relevant The study investigates the therapeutic inducibility of tertiary lymphoid structures using a lymphotoxin-beta receptor agonist combined with PD-L1 blockade in a syngeneic bladder cancer model and assesses immune microenvironment remodeling. | lymphotoxin-beta receptor agonist; PD-L1 blockade | Animal | bladder cancer | lymphotoxin-beta receptor agonist 0/0/0; PD-L1 blockade 0/4/0 | Awaiting curator check |
| 42378823 | 2026 | An engineered oncolytic vaccinia virus expressing PD-L1 inhibitor exerts anti-tumor effects on glioblastoma by activating T cell responses. International immunopharmacology Likely relevant The study experimentally tests an engineered oncolytic vaccinia virus and anti-PD-1 therapy in glioblastoma cell co-cultures and orthotopic animal models, measuring T cell activation, infiltration, and regulatory T cells. | VV-iPDL1/GM; anti-PD-1 therapy | Mixed | glioblastoma | VV-iPDL1/GM 0/0/0; anti-PD-1 therapy 0/0/0 | Awaiting curator check |
| 42438795 | 2026 | Shuyu Wan Potentiates PD-1 Inhibitor Efficacy in Non-Small Cell Lung Cancer: Integrated Bioinformatics and Experimental Evidence for Gut Microbiota-Tumor Immune Crosstalk. Drug design, development and therapy Likely relevant The study experimentally tests Shuyu Wan and a PD-1 inhibitor in NSCLC syngeneic mice and measures effects on serum cytokines, tumor-infiltrating CD8+ T cell infiltration, exhaustion, and effector phenotypes. | PD-1 inhibitor; RMP1-14; Shuyu Wan | Animal | Non-Small Cell Lung Cancer | PD-1 inhibitor 0/0/0; RMP1-14 0/0/0; Shuyu Wan 0/0/0 | Awaiting curator check |